Rocket Pharmaceuticals Inc stock is traded at $2.44, with a volume of 2,182,207. It is down -6.70% in the last 24 hours and down -6.70% over the past month. Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Previous Close:
$2.61
Open:
$2.60
24h Volume:
2,182,207
Relative Volume:
1.29
Market Cap:
$267.30M
Revenue:
-
Net Income/Loss:
-$209.38M
P/E Ratio:
-
EPS:
-$1.88
Net Cash Flow:
-$179.81M
1W Performance:
-4.13%
1M Performance:
-6.70%
6M Performance:
-31.21%
1Y Performance:
-26.66%
1-Day Range:
$2.30$2.60
1-Week Range:
$2.30$2.66
52-Week Range:
$2.17$5.45
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
646-440-9100Address
350 FIFTH AVENUE, NEW YORK, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS